Heron Therapeutics Files 8-K

TL;DR

HRTX filed an 8-K today, likely containing regulatory disclosures or financial updates.

AI Summary

On December 23, 2024, Heron Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This 8-K filing indicates Heron Therapeutics is providing updates or disclosures to the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

• Heron Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• 001-33221 (commission_file_number) — SEC File Number
• 94-2875566 (irs_number) — I.R.S. Employer Identification No.
• 100 Regency Forest Drive, Suite 300, Cary, NC 27518 (address) — Principal executive offices
• (858) 251-4400 (phone_number) — Registrant's telephone number
• 4242 Campus Point Court, Suite 200, San Diego, CA 92121 (address) — Business address
• AP PHARMA INC /DE/ (company) — Former company name
• ADVANCED POLYMER SYSTEMS INC /DE/ (company) — Former company name

FAQ

From the Filing

0000950170-24-139569.txt : 20241223 0000950170-24-139569.hdr.sgml : 20241223 20241223160508 ACCESSION NUMBER: 0000950170-24-139569 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20241223 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241223 DATE AS OF CHANGE: 20241223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HERON THERAPEUTICS, INC. /DE/ CENTRAL INDEX KEY: 0000818033 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 942875566 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33221 FILM NUMBER: 241573586 BUSINESS ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582514400 MAIL ADDRESS: STREET 1: 4242 CAMPUS POINT COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: AP PHARMA INC /DE/ DATE OF NAME CHANGE: 20010511 FORMER COMPANY: FORMER CONFORMED NAME: ADVANCED POLYMER SYSTEMS INC /DE/ DATE OF NAME CHANGE: 19920703 8-K 1 hrtx-20241223.htm 8-K 8-K false 0000818033 0000818033 2024-12-23 2024-12-23 0000818033 dei:FormerAddressMember 2024-12-23 2024-12-23   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Heron Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33221 94-2875566 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Regency Forest Drive , Suite 300 , Cary , NC 27518 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (858) 251-4400 4242 Campus Point Court , Suite 200 , San Diego , CA , 92121 (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share HRTX The Nasdaq  Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 7.01 Regulation FD Disclosure.   On December 23, 2024, Heron Therapeutics, Inc. issued a press release announcing the relocation of its corporate headquarters from San Diego, California to Cary, North Carolina. Such press release is attached hereto and furnished as Exhibit 99.1. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, no